MedTrace Logo

Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration

NCT00423189 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-03-04

Study results available
· View outcomes & findings →

Summary

The PDT/Lucentis trial will be a Phase IV comparative trial comparing the use of combination therapy with ITV ranibizumab and verteporfin PDT to ITV ranibizumab alone in patients with exudative AMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Ranibizumab (Lucentis)

as needed, one intravitreal injection of 0.50mg ranibizumab

DRUG

0.5mg ranibizumab

as needed, one intravitreal injection of 0.50mg ranibizumab

Sponsors & Collaborators

Principal Investigators

  • David M Brown, M.D. · Vitreoretinal Consultants

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00423189 on ClinicalTrials.gov